Clinical Trial Update: JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating JDB153 in combination with Serplulimab for refractory pancreatic ductal adenocarcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• JDB153 (JDB153)
• Serplulimab (serplulimab)

Snippet

Sponsor: West China Hospital | Conditions: Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING